Oncology News | pharmaphorum

News

Transgene cervical cancer shot misses the mark in phase 2

Transgene's therapeutic vaccine for cervical and anogenital cancers has failed a phase 2 trial, but an efficacy signal warrants further study

News

Ono, Boehringer add to cancer pipelines with licensing deals

Ono Pharma and Boehringer Ingelheim both added to their cancer pipelines, licensing drugs from LigaChem Bio and Circle Pharma, respectively.

News

breast cancer awareness campaign - women in front of Westminster

UK celeb seeks funds to challenge NICE's Enhertu verdict

UK actor and TV personality Nadia Sawalha is spearheading a fundraising effort to launch an appeal against the recent rejection of a breast cancer therapy by cost-effectiveness agency NICE.

News

GSK says $2.2bn settlement resolves most Zantac litigation

GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer.

News

NICE turns down Takeda colorectal cancer drug

Takeda's recently approved advanced colorectal cancer therapy Fruzaqla has been rejected by NICE for use by the NHS on the grounds that it is not cost-effective.

News

Setback for J&J's TAR-200 bladder cancer programme

A phase 3 trial of Johnson & Johnson's TAR-200 therapy in bladder cancer has failed to show efficacy, although the company is still confident in the potential of the programme.

Transgene cervical cancer shot misses the mark in phase 2

Ono, Boehringer add to cancer pipelines with licensing deals

UK celeb seeks funds to challenge NICE's Enhertu verdict

GSK says $2.2bn settlement resolves most Zantac litigation

NICE turns down Takeda colorectal cancer drug

Setback for J&J's TAR-200 bladder cancer programme

Lilly partners with Hims & Hers on obesity drug sales

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks